



## Ultragenyx to Present at Upcoming Investor Conferences

June 4, 2018

NOVATO, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences:

- Jayson Dallas, M.D., the company's Chief Commercial Officer, will present at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 3:00 pm ET in New York.
- Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the Goldman Sachs 39<sup>th</sup> Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 2:40 pm PT in Rancho Palos Verdes, CA.
- Tom Kassberg, the company's Chief Business Officer, will present at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018 at 11:00 am ET in New York.

The live and archived webcasts of the company's presentations will be accessible from the company's website at <http://ir.ultragenyx.com/events.cfm>. The replay of the webcasts will be available for 90 days.

### About Ultragenyx

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at [www.ultragenyx.com](http://www.ultragenyx.com).

Contact Ultragenyx Pharmaceutical Inc.  
Investors & Media  
Danielle Keatley  
415-475-6876

 [Primary Logo](#)

Source: Ultragenyx Pharmaceutical Inc.